ISOVUE Comparative Trial (ISOVUE)

January 14, 2026 updated by: Rush University Medical Center

ISOVUE Contrast for Intraoperative Assessment of Discectomy Quality in TLIF: A Prospective Randomized Trial

This study aimed to investigate a novel technique for intraoperative quantitative and qualitative feedback during discectomy and endplate preparation in TLIF.

Study Overview

Detailed Description

The purpose of this study was to introduce a novel surgical technique using ISOVUE-300M contrast dye for intraoperative visualization of discectomy progress and to test the value of this technique by comparing outcomes of two patient cohorts. The investigators hypothesize that the standard TLIF technique results in a surprisingly low percentage of effective disc preparation, even when performed by an experienced TLIF surgeon. Secondly, the investigators hypothesize that by using intraoperative visual feedback to guide a second discectomy pass that the extent of disc space preparation can be substantially improved compared to patients where visual feedback is not available. Lastly, the investigators aim to conduct a clinical outcomes analysis evaluating radiographic and complication outcomes. To the best of the authors' knowledge, this prospective study is the first to evaluate differences in disc space preparation using a novel contrast-based technique while also providing clinical outcomes.

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60612
        • Rush University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients undergoing open circumferential transforaminal lumbar interbody fusion or midline cortical TLIF for degenerative spondylolisthesis

Exclusion Criteria:

  • All not in the group above

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Observation
In the Observation group, after initial discectomy and endplate preparation, ISOVUE-300M contrast was administered into the disc space and orthogonal anterior-posterior and lateral radiographs were obtained. The case then proceeded with graft and cage insertion without additional disc excision or endplate work.
In the Observation group, after initial discectomy and endplate preparation,ISOVUE-300M contrast was administered into the disc space and orthogonal anterior-posterior and lateral radiographs were obtained. The case then proceeded with graft and cage insertion without additional disc excision or endplate work.
Experimental: Feedback
In the Feedback group, the surgeon was permitted to utilize the ISOVUE imaging as a feedback mechanism to then re-prepare the disc space prior to final graft/cage insertion. An additional dose of ISOVUE-300M was administered into the disc space with repeat radiographs obtained prior to grafting/cage insertion to demonstrate the effect of the second pass of disc and cartilage removal.
In the Feedback group, the surgeon was permitted to utilize the ISOVUE imaging as a feedback mechanism to then re-prepare the disc space prior to final graft/cage insertion. An additional dose of ISOVUE-300M was administered into the disc space with repeat radiographs obtained prior to grafting/cage insertion to demonstrate the effect of the second pass of disc and cartilage removal.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anteroposterior Plane Clearance
Time Frame: Immediately after Discectomy
Disc space clearance in the anteroposterior (AP) plane at the index level measured on oblique radiographs.
Immediately after Discectomy
Mediolateral Plane Clearance
Time Frame: Immediately after Discectomy/Excision Intraoperatively
Disc space clearance in the mediolateral (ML) plane as measured by oblique radiographs.
Immediately after Discectomy/Excision Intraoperatively
Visual Analog Scale
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
Visual Analog Scale survey assessing leg pain and back pain
First Postoperative Clinic Appointment (within first 6 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lumbar Lordosis
Time Frame: Immediately after Discectomy Intraoperatively
Lumbar Lordosis as measured by oblique radiographs.
Immediately after Discectomy Intraoperatively
Pelvic Incidence
Time Frame: Immediately after Discectomy Intraoperatively
Pelvic incidence (PI) as measured by oblique radiographs.
Immediately after Discectomy Intraoperatively
Disc Height
Time Frame: Immediately after Discectomy Intraoperatively
Disc height at the index level as identified by oblique radiographs.
Immediately after Discectomy Intraoperatively
Oswestry Disability Index
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
Oswestry Disability Index survey describing disability as a result of spinal conditions.
First Postoperative Clinic Appointment (within first 6 weeks)
Short Form Survey
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
SF-12 survey asking patient views about health
First Postoperative Clinic Appointment (within first 6 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 11, 2019

Primary Completion (Actual)

June 19, 2023

Study Completion (Actual)

June 19, 2023

Study Registration Dates

First Submitted

January 7, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 23, 2026

Study Record Updates

Last Update Posted (Actual)

January 23, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 18072502-IRB02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The investigators will consider sharing if contacted with reasonable requests.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Degenerative Disc Disease

Clinical Trials on ISOVUE 300 Observation

Subscribe